The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Abstract
The increasing prevalence of Alzheimer's disease represents a global challenge at multiple levels: personal, social, and economic. The amyloid hypothesis1 posits that deposition of amyloid-beta (Aβ) in brain parenchyma is an early critical event in Alzheimer's disease that promotes or accelerates downstream features of the disease such as tangle formation, neuronal loss, and progressive dementia. Most pharmaceutical companies seeking disease-modifying treatments for Alzheimer's disease have investigated Aβ-centric therapeutics.This issue of the Journal contains reports on the phase 3 trials in Alzheimer's disease of two anti-Aβ antibodies: bapineuzumab2 and solanezumab.3 Each agent was tested in two trials. Both sets of . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [458]
In the citing paper
“Biomarker testing reduces dementia misdiagnoses: when biomarkers are not used, the rate of misdiagnosis is approximately 25–35% in specialty clinics and even higher in primary care clinics4,12,13.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [13]
In the citing paper
“Clinical trials in AMCI and AD have thus far been disappointing [8]”
From Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial (2016) · cites this paper as [8]
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442
Maia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204
Research works printed but not linked: 2
- 10.1056/nejmoa1304839 · DOI · Paper page
- 10.1056/nejmoa1312889 · DOI · Paper page
Cited by
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
“Earlier AD drug trials recruited participants with a clinical syndrome of AD dementia, but approximately 25% of study participants did not have detectable brain amyloidosis.(7) Recent AD drug trials have used CSF biomarkers and amyloid PET to screen potential participants for brain amyloidosis.”
BackgroundThe Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
“Such tactics may be earlier intervention within the disease continuum and better criteria for patient selection [5, 108] and better biomarkers for monitoring of investigational new drugs [103], including inflammation markers to better predict complications [106].”
Background
Metadata
- Authors
- Karran, E., & Hardy, J.
- Affiliations
- Alzheimer’s Research UK (GB)
- University College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 377-378
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2030067782
- Cited by
- 126
- References
- 7
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 7 · 2023: 1 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 9 · 2017: 7 · 2016: 19 · 2015: 26 · 2014: 24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, amyloid-beta, anti-amyloid therapy, amyloid hypothesis, bapineuzumab, solanezumab, anti-amyloid antibodies, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Female, Humans, Male, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road? https://app.cochat.ai/papers/10.1056/nejme1313943
- The paper
- Karran, E., & Hardy, J. (2014). Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road? New England Journal of Medicine. https://doi.org/10.1056/nejme1313943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.